|
Protocol Number:
99-CC-0013
- Title:
Sonographic Evaluation of the Effects of Raloxifene on the Uterus and Ovaries in Premenopausal Patients at High Risk for Developing Breast Cancer
- Number:
99-CC-0013
- Summary:
This research study is designed to work in cooperation with another study being conducted by the National Cancer Institute. The National Cancer Institute (NCI) is studying the effects of a drug called raloxifene on premenopausal women believed to have a high risk of developing breast cancer (98-C-0123).
In this study, researchers are interested in learning about the effects of raloxifene on the uterus and ovaries of the women participating in the NCI study. To do this researchers plan to conduct ultrasounds on the patients enrolled in the NCI study. In addition researchers plan to take samples of the lining of the uterus in these patients (endometrial biopsy) if found to be necessary.
The purpose of this study is to determine the reproductive effects of raloxifene on women who have normal functioning ovaries by taking ultrasounds of the ovaries and lining of the uterus (endometrium).
- Sponsoring Institute:
-
Warren G. Magnuson Clinical Center (CC)
- Recruitment Detail
- Type:
Follow-up Of Previously Enrolled Subjects Only
- Gender:
Female
- Referral Letter Required:
Yes
- Population Exclusion(s):
Male
Children
- Eligibility Criteria:
This study is not currently recruiting new subjects. If you have questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
- Special Instructions:
Currently Not Provided
- Disease Category:
-
PROTICD
- Keywords:
-
Sonohysterography
-
Color Doppler Sonography
-
Endometrium
-
Gynecologic
-
Menstrual Cycle
- Recruitment Keywords:
-
Premenopause
- Conditions:
-
Breast Cancer
-
Breast Neoplasm
- Investigational Drug(s):
- None
- Investigational Device(s):
- None
- Contacts:
-
This study is not currently recruiting new subjects. If you have questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
- Citations:
-
Tamoxifen for the prevention of breast cancer: Report of the National Surgical Adjuvent Breast and Bowel project P1 study
-
Gynaecological cytology and pelvic ultrasonography in patients with breast cancer taking tamoxifen compared with controls
-
Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer
If you have:
Search The Studies | Help | Questions | Clinical Center Home | NIH Home
Warren Grant Magnuson Clinical Center (CC) National Institutes of Health (NIH)
Bethesda, Maryland 20892. Last update: 10/23/2004
|
|